Refine your results

to


Search

Sorafenib benefit dependent on hepatitis status in patients with HCC

Show Citation

February 19, 2017

AUTHORS:

Jackson R, Psarelli E-E, Berhane S, Khan H, Johnson P.

PURPOSE:

Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib has become the standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survival advantage and disease etiology remains unclear. ...

Advertisement
Advertisement